EU approves use of apepox vaccine

The European Commission has approved the use of smallpox vaccine against monkeypox, as the World Health Organization declared the freedom of global emergency health monkeys, said drug producer from Denmark.

The European Commission has extended the authorisation of the company's smallpox vaccine, Imvanex, to include it in the protection against monkey pox”, in line with the recommendation of EU healthcare observers, the Bavrian Nordic company said.

The approval is valid for all European Union member states, as well as Iceland, Litenstein and Norway”, the company said.

On Saturday, February 23rd, WHO declared the release of global emergency health monkeys. To date, 16,000 people in 72 countries in the world have been affected by monkeypoke.

In the EU since 2013, Imvanex vaccine has been approved for use against smallpox.

Earlier, the use of a smallpox vaccine was considered because of the similarity of viruses that cause smallpox and monkeypox.

The monkey's line is less dangerous and less infectious than the oak, which disappeared in 1980.

Monkey oak symptoms are temperature, headache, muscle and back pain. The symptoms last for five days.

Also, the affected have frying faces on their hands and feet and rashes.

The new eruption of monkey smallpox was reported in the countries of Central and West Africa in early May, where the disease has long been epidemic. / REL